Abstract book - ESTRO meets Asia

S7 ESTRO meets Asia 2018

( 4 pts ). TMI (4Gy x 2 fx) + thiotepa + fludarabine + busulfan for advanced LAM patients ( 4 pts ). TMI as the boost (2- 3Gy) after conventional TBI was (12 Gy in 6 bi-fractionated doses) by cyclophosphamide ( 18 pts ). Autologous preparation to SCT consisted of TLI (4Gyx 3fx) followed by high-dose bendamustine and melphalan for patients older than 40 years and conventional FEAM (Fotemustine, Etoposide, Cytarabine, and Melphalan) for younger patients, in HD e NHL ( 20 pts ). While TMI (4Gy x 3 fx) plus melphalan was delivered for autologous SCT in MM and LAM ( 12 pts ). No unexpected acute toxicity was found. In the allogenic setting, all the patients’ engraftment was achieved in all patients. No acute graft versus host disease increasing was detected. Within the autologous setting, only 33% developed grade 3/4 mucositis. None experienced grade 3/4 extra-hematological toxicity. Outcomes of the specific disease will be reported. Conclusion The current report describes the clinical feasibility of using HT to deliver TMI or TLI in the setting of autologous transplantation or during allogenic stem cell conditioning regimen, to allow all patients (old, fragile or with high tumor burden) to achieve an ablative regimen before SCT. To our knowledge, this single institution experience describes data from one of the largest cohort of patients treated in Europe since the development of this irradiation techniques. OC-020 The value of prognostic nutritional index in follicular lymphoma S.F. Lee 1 , T.Y. Ng 1 , F.C.S. Wong 1 1 Tuen Mun Hospital, Department of Clinical Oncology, Tuen Mun, Hong Kong SAR China Purpose or Objective Previous studies reported that prognostic nutritional index (PNI), a marker of host inflammatory and nutritional status, is associated with prognoses in a number of cancer types. Thus, we investigated PNI at diagnosis as a prognostic factor in follicular lymphoma (FL). Material and Methods We reviewed FL patients in Tuen Mun Hospital, Hong Kong from 2000 to 2014 (n = 88). PNI was calculated by serum albumin (g/L) + 5 x absolute lymphocyte count (10 9 /L). We determined the best PNI cut-off value using receiver- operating characteristic curves. The extent to which progression-free survival (PFS) and overall survival differed by PNI cut-off was assessed using Kaplan–Meier and logrank tests. Cox proportional hazards model was utilized to adjust for covariates. Results The best cut-off value for PNI was determined to be 45. Patients with high PNI (>45) had a higher complete response (CR) rate after primary treatment, 46 out of 61 (75.4%) patients with high PNI had CR, compared with 10 out of 23 (43.5%) for low PNI (Two-sample test of proportions p-value = 0.006). Further, PNI at relapse as a continuous variable was associated with post-progression survival with a hazard ratio (HR) 0.88 (95% confidence interval [CI] 0.81–0.96). In multivariate analysis (see Table 1 and Figure 1), high PNI at diagnosis had superior PFS (adjusted HR of 0.37, 95%CI 0.15–0.93).

Table 1. Multivariate analyses for PFS of PNI at diagnosis, n = 88.

Figure 1. Adjusted PFS predicted by different levels of PNI. PFS estimates of high and low PNI at diagnosis (n = 88).Grey lines denote upper and lower 95% confidence limits. Conclusion PNI was shown to be an independent prognostic factor of PFS in FL. It is low cost and widely available biomarker for predicting prognosis. Future study is needed to validate our finding in a prospective cohort. OC-021 IMRT plus S-1 chemotherapy in locally advanced nasopharyngeal carcinoma:a multicenter phase II study X. Wang 1 , T. Lv 1 , Y. Wang 1 , L. Liu 2 , P. Lou 3 , S. Qin 4 1 Fudan University Shanghai Cancer Center, Department of Radiation Oncology, Shanghai, China 2 Taizhou Cancer Hospital, Department of Radiation Oncology, Wenling, China 3 Ningbo First Hospital, Center of Chemoradio-oncology, Ningbo, China 4 the First Affiliated Hospital of Soochow University, Department of Radiation Oncology, Soochow, China Purpose or Objective The standard treatment for patients with locally advanced nasopharyngeal carcinoma (NPC) is intensity-modulated radiation therapy (IMRT) combined with cisplatin concurrent chemoradiotherapy. However, the toxicities related to cisplatin-based chemoradiotherapy can not be ignored. The compliance rate was relatively poor. Many studies have reported that S-1 was effective with mild toxicities in multiple solid cancers. But, knowledge is lacking regarding the combination of S-1 and IMRT for locally advanced NPC. Therefore, we conducted this multicenter phase II trial to evaluate the efficacy and safety of IMRT combined with S-1 concurrent chemoradiotherapy in patients with locally advanced NPC. Material and Methods Patients with histologically confirmed locally advanced NPC but without chemotherapy contraindications were eligible for this study. IMRT was administrated as follow ，